Leridip

Lercanidipine, the active ingredient in Leridip, is a calcium channel blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure through vascular smooth‑muscle relaxation.

GNH USA supplies Leridip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Leridip (l ercanidipine) is used to treat conditions related to elevated blood pressure.

Hypertension: reduces systolic and diastolic blood pressure to target levels. Essential hypertension: provides long‑term blood pressure control. Secondary hypertension (adjunct): assists in managing blood pressure when other causes are present. Elderly hypertension: offers once‑daily dosing suitable for older patients. Hypertensive patients requiring combination therapy: can be combined with other antihypertensives for additive effect.

Leridip may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Palpitations: sensation of irregular heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare cardiac event. - Arrhythmias: abnormal heart rhythms. - Hepatic dysfunction: elevated liver enzymes. - Stevens‑Johnson syndrome: severe skin reaction. - Angioedema: swelling of face, lips, or throat.

Before initiating therapy with Leridip, consider the following precautions.

Monitor blood pressure: ensure adequate control and avoid excessive drops. Assess hepatic function: adjust use in patients with liver impairment. Use caution in the elderly: increased sensitivity to hypotensive effects. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Review concomitant CYP3A4 inhibitors: may increase drug exposure. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Leridip can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Concurrent use with other potent antihypertensives: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Grapefruit juice: can modestly increase drug exposure. - Diuretics: may enhance electrolyte disturbances. - Beta‑blockers: may increase risk of bradycardia. - NSAIDs: may attenuate antihypertensive effect. - Antacids containing aluminum or magnesium: may affect absorption.